NanoLogix Inc (NNLX)

[Emerald Isle]

When is the World going to awaken to the potential of Nanologix?


Reception of the NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli Presented at the American Society for Microbiology (ASM Microbe) Annual meeting


Novel Rapid Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7

Jonathan Faro, MD, PhD and Sebastian Faro, MD, PhD, medical researchers presenting the technology poster at the ASM Annual meeting in New Orleans this past weekend stated:

"ASM Microbe was a very stimulating meeting. We enjoyed meeting many investigators and the engaging discussions that followed. Of the many rapid ID tests either on the market or the many more that presented and will soon be available, our assay is the most unique, and has the ability to provide the greatest limit of detection while simultaneously determining antibiotic susceptibility."

Further information from NanoLogix metrics monitoring indicated interest from at least two major laboratories. 

The N-Assay is currently undergoing development for rapid detection of Urinary Tract Infections (UTI) and we anticipate the N-Assay to be debuted soon as the definitive UTI test for speed, accuracy, and sensitivity. 

Two published examples of the N-Assay and its performance can be accessed through the following links:

https://www.hindawi.com/journals/idog/2016/5293034/

http://nanologix.com/news/poster-e-coli-0157.pdf


The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B
Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.